Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: An international, multicenter study

Simple item page
dc.contributor.authorAlptekin K.
dc.contributor.authorHafez J.
dc.contributor.authorBrook S.
dc.contributor.authorAkkaya C.
dc.contributor.authorTzebelikos E.
dc.contributor.authorUcok A.
dc.contributor.authorTallawy H.E.
dc.contributor.authorDanaci A.-E.
dc.contributor.authorLowe W.
dc.contributor.authorKarayal O.N.
dc.date.accessioned2024-07-22T08:21:58Z
dc.date.available2024-07-22T08:21:58Z
dc.date.issued2009
dc.description.abstractTo compare the effectiveness of a switch from haloperidol (N=99), olanzapine (N=82), or risperidone (N=104) to 12 weeks of treatment with 80-160 mg/day ziprasidone in patients with stable schizophrenia or schizoaffective disorder. Stable outpatients with persistent symptoms or troublesome side effects were switched using one of three 1-week taper/switch strategies as determined by the investigator. Efficacy was assessed using the Brief Psychiatric Rating Scale score, Clinical Global Impression, Positive and Negative Symptom Scale, Montgomery-Åsberg Depression Rating Scale, and the Global Assessment of Functioning Scale, and tolerability by using standard measures of weight change, extrapyramidal symptoms, and laboratory findings. Suboptimal efficacy was the primary reason for switching. The preferred switch strategy was immediate discontinuation, and the preferred dosing regimen was 120 mg/day. Completer rates were 68, 60, and 86% in the haloperidol, risperidone, and olanzapine pre-switch groups, respectively. At week 12, a switch to ziprasidone resulted in statistically significant improvement from baseline on the Brief Psychiatric Rating Scale score, Clinical Global Impression- Improvement, Positive and Negative Symptom Scale, and Global Assessment of Functioning scales, reduction in extrapyramidal symptoms and a neutral impact on metabolic parameters. Switch from olanzapine and risperidone resulted in weight reduction and from haloperidol in some weight increase. In conclusion, oral ziprasidone of 80-160 mg/day with food was a clinically valuable treatment option for stable patients with schizophrenia or schizoaffective disorder experiencing suboptimal efficacy or poor tolerability with haloperidol, olanzapine, or risperidone. © 2009 Lippincott Williams & Wilkins, Inc.
dc.identifier.DOI-ID10.1097/YIC.0b013e32832c2624
dc.identifier.issn02681315
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/18868
dc.language.isoEnglish
dc.publisherLippincott Williams and Wilkins
dc.subjectantiparkinson agent
dc.subjectanxiolytic agent
dc.subjectbenzodiazepine
dc.subjectcholinergic receptor blocking agent
dc.subjecthaloperidol
dc.subjecthypnotic sedative agent
dc.subjectlorazepam
dc.subjectolanzapine
dc.subjectpropranolol
dc.subjectrisperidone
dc.subjectziprasidone
dc.subjectzolpidem
dc.subjectadult
dc.subjectaged
dc.subjectakathisia
dc.subjectanxiety disorder
dc.subjectarticle
dc.subjectbehavior disorder
dc.subjectBrief Psychiatric Rating Scale
dc.subjectClinical Global Impression scale
dc.subjectclinical trial
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectdizziness
dc.subjectdrug dose reduction
dc.subjectdrug dose titration
dc.subjectdrug efficacy
dc.subjectdrug substitution
dc.subjectdrug tolerability
dc.subjectdrug withdrawal
dc.subjectextrapyramidal symptom
dc.subjectfemale
dc.subjectfood
dc.subjectheadache
dc.subjecthuman
dc.subjectinsomnia
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmetabolic parameters
dc.subjectMontgomery Asberg Depression Rating Scale
dc.subjectmulticenter study
dc.subjectnausea
dc.subjectopen study
dc.subjectpatient compliance
dc.subjectPositive and Negative Syndrome Scale
dc.subjectpriority journal
dc.subjectrating scale
dc.subjectschizoaffective psychosis
dc.subjectschizophrenia
dc.subjectside effect
dc.subjectsomnolence
dc.subjecttreatment duration
dc.subjectunspecified side effect
dc.subjectweight
dc.subjectweight change
dc.subjectweight gain
dc.subjectweight reduction
dc.titleEfficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: An international, multicenter study
dc.typeArticle

Files

Collections

Scopus Koleksiyonu